FierceBiotechOriginal article
{"a":[{"_":"Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trial","$":{"href":"/biotech/kolons-cell-based-gene-therapy-fails-phase-3-osteoarthritis-trial","hreflang":"en"}}]}
Phase 3negativeTissueGene cell-based gene therapyNegative
AI Analysis
Summary
Kolon TissueGene's Phase 3 trial of its cell-based gene therapy for osteoarthritis failed to meet co-primary endpoints. A second late-stage study is scheduled to report data in October 2026.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Missed co-primary endpoints
Importance:7/10
Sentiment:
-0.85
Phase 3 failureGene therapyCell-based therapyOsteoarthritisClinical trial
Read the original article
Published by FierceBiotech on July 20, 2026 9:25 AM